Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
AZD-5851 by AstraZeneca for Hepatocellular Carcinoma: Likelihood of Approval
AZD-5851 is under clinical development by AstraZeneca and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...